HomeCompareOLMIY vs ABBV

OLMIY vs ABBV: Dividend Comparison 2026

OLMIY yields 47.49% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 OLMIY wins by $32.54M in total portfolio value
10 years
OLMIY
OLMIY
● Live price
47.49%
Share price
$25.02
Annual div
$11.88
5Y div CAGR
23.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32.65M
Annual income
$21,855,504.05
Full OLMIY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — OLMIY vs ABBV

📍 OLMIY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodOLMIYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, OLMIY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
OLMIY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

OLMIY
Annual income on $10K today (after 15% tax)
$4,036.82/yr
After 10yr DRIP, annual income (after tax)
$18,577,178.44/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, OLMIY beats the other by $18,556,122.44/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of OLMIY + ABBV for your $10,000?

OLMIY: 50%ABBV: 50%
100% ABBV50/50100% OLMIY
Portfolio after 10yr
$16.37M
Annual income
$10,940,137.91/yr
Blended yield
66.81%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

OLMIY
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

OLMIY buys
0
ABBV buys
0
No recent congressional trades found for OLMIY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricOLMIYABBV
Forward yield47.49%3.06%
Annual dividend / share$11.88$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR23.7%40.6%
Portfolio after 10y$32.65M$102.3K
Annual income after 10y$21,855,504.05$24,771.77
Total dividends collected$31.54M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: OLMIY vs ABBV ($10,000, DRIP)

YearOLMIY PortfolioOLMIY Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$16,575$5,874.77$11,550$430.00+$5.0KOLMIY
2$28,992$11,257.04$13,472$627.96+$15.5KOLMIY
3$53,785$22,763.62$15,906$926.08+$37.9KOLMIY
4$106,371$48,821.42$19,071$1,382.55+$87.3KOLMIY
5$225,442$111,624.51$23,302$2,095.81+$202.1KOLMIY
6$514,722$273,498.60$29,150$3,237.93+$485.6KOLMIY
7$1,272,655$721,902.52$37,536$5,121.41+$1.24MOLMIY
8$3,425,232$2,063,491.49$50,079$8,338.38+$3.38MOLMIY
9$10,085,486$6,420,488.06$69,753$14,065.80+$10.02MOLMIY
10$32,646,974$21,855,504.05$102,337$24,771.77+$32.54MOLMIY

OLMIY vs ABBV: Complete Analysis 2026

OLMIYStock

Olam Group Limited engages in the sourcing, processing, packaging, and merchandising of agricultural products worldwide. It operates through Olam Food Ingredients, Olam Global Agri, and Olam International Limited segments. The company offers cocoa powder, liquor, and butter, as well as specialty fats, such as vegetable fats, cocoa butter equivalent fats, cocoa butter improver fats, cocoa butter substitutes, and confectionery and custom fats under the under the deZaan, Unicao, Joanes, Macao, Huysman, Britannia, and BT Cocoa brands; coffee; whole, skimmed, and butter milk powders; butter, anhydrous milk fat, and butter blends; cheese; milk and whey protein concentrates, permeates, and lactose; nuts, including almonds, cashews, hazelnuts, peanuts, sesame, and quinoa and chia seeds; and spices, comprising of chillies, onion and garlic, and pepper. It also provides cotton; palm, soybean, and sunflower oils; animal feeds and proteins; flours for breads, baguettes, pasta noodles, biscuits, semolina, and confectionery; fish feeds; rubber; rice; and timber products. In addition, the company offers biscuits under the Perk, King Cracker, Pure Bliss, and Chic Choc brands; tomato mix under the Tasty Tom, De Rica, and Festin brand names; Tasty Tom Jollof Mix; drinking yoghurt under the FreshYo brand; lollipops under the OK Pop brand name; and noodles under the Cherie Noodles, Cherie Supa Chicken, and Tasty Tom brands. Further, the company engages in the poultry breeding farm and day-old-chick hatchery business; and provision of commodity financial, risk management, and infrastructure and logistics services, as well as sourcing solutions for agricultural raw materials and food ingredients. Olam Group Limited was founded in 1989 and is headquartered in Singapore.

Full OLMIY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this OLMIY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

OLMIY vs SCHDOLMIY vs JEPIOLMIY vs OOLMIY vs KOOLMIY vs MAINOLMIY vs JNJOLMIY vs MRKOLMIY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.